AlloNK Shows Strong Sjögren Efficacy and Clean Safety in Phase 2a
ARTV has more than doubled off its 52-week low of $2.71.
Summary
Artiva reported updated Phase 2a data for AlloNK plus rituximab in Sjögren disease, showing mean ClinESSDAI −6.9 and ESSPRI −3.5 at 6 months in 11 patients, with salivary flow improving from 0.4 to 1.1 mL/min. No CRS or ICANS occurred across 73 patients in the basket study, supporting outpatient use. This follows the Q2 RMAT designation and builds on earlier EULAR data, strengthening the case for AlloNK in autoimmune diseases. The company also confirmed a Phase 3 trial in refractory RA is set to begin in H2'26, providing a clear registrational path. These results validate the B-cell depletion approach and could support broader autoimmune utility, though the small sample size and lack of a control arm remain key limitations.
At the time of this announcement, ARTV was trading at $7.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $348.1M. The 52-week trading range was $2.71 to $14.53. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.